Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (5)

• Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study Endpoints News · 12h ago
• Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS Fierce Biotech · 12h ago
• Roche drug sets new standard for KRAS-driven lung cancer STAT · 12h ago
• Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study FirstWord PHARMA · 12h ago
• Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial WSJ · 12h ago

Related trends